Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04024696 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04024696 · ClinicalTrials.gov record · last posted 2025-04-10

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

StatusActive, Not Recruiting
PhasePhase 1/2
Started2020-01-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an open-label, non-randomized clinical study to evaluate the pharmacokinetic (PK) profiles, safety, tolerability and preliminary efficacy of oral abexinostat monotherapy in patients with non-Hodgkin's lymphoma who have failed standard of care, and thereby to determine the pharmacokinetic (PK) parameters, the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of the oral monotherapy of abexinostat.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2019-07-16; most recent amendment 2025-04-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-01-22
Status change Recruiting→Active, Not Recruitingv5
2020-01-15
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04024696
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Non Hodgkin Lymphoma
Enrollment 12 participants
Start Date 2020-01-08
Primary Completion 2024-12-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-10